[{"address1": "2265 Upper Middle Road East", "address2": "Suite 602", "city": "Oakville", "state": "ON", "zip": "L6H 0G5", "country": "Canada", "phone": "289-910-0850", "fax": "905-481-2394", "website": "https://www.cardiolrx.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.", "companyOfficers": [{"maxAge": 1, "name": "Mr. David G. Elsley MBA", "title": "President, CEO & Director", "fiscalYear": 2023, "totalPay": 556250, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher J. Waddick C.A., C.M.A., CPA, CMA, MBA", "title": "CFO, Corporate Secretary & Director", "fiscalYear": 2023, "totalPay": 219199, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bernard  Lim B.Sc.", "title": "Chief Operating Officer", "fiscalYear": 2023, "totalPay": 383597, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andrew Warwick Hamer M.D.", "age": 61, "title": "Chief Medical Officer & Head of Research & Development", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 555107, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Trevor  Burns", "title": "Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.88, "open": 1.92, "dayLow": 1.87, "dayHigh": 1.94, "regularMarketPreviousClose": 1.88, "regularMarketOpen": 1.92, "regularMarketDayLow": 1.87, "regularMarketDayHigh": 1.94, "beta": 0.691, "forwardPE": -6.2580647, "volume": 186210, "regularMarketVolume": 186210, "averageVolume": 440642, "averageVolume10days": 215980, "averageDailyVolume10Day": 215980, "bid": 1.92, "ask": 1.95, "bidSize": 100, "askSize": 400, "marketCap": 135570496, "fiftyTwoWeekLow": 0.661, "fiftyTwoWeekHigh": 3.12, "fiftyDayAverage": 2.0405, "twoHundredDayAverage": 1.67068, "currency": "USD", "enterpriseValue": 111713576, "floatShares": 66621039, "sharesOutstanding": 69881696, "sharesShort": 752513, "sharesShortPriorMonth": 767721, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0108, "heldPercentInsiders": 0.045679998, "heldPercentInstitutions": 0.11314999, "shortRatio": 2.93, "shortPercentOfFloat": 0.0113, "impliedSharesOutstanding": 71155200, "bookValue": 0.222, "priceToBook": 8.738739, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -29337708, "trailingEps": -0.33, "forwardEps": -0.31, "enterpriseToEbitda": -3.528, "52WeekChange": 0.90196073, "SandP52WeekChange": 0.2560848, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "CRDL", "underlyingSymbol": "CRDL", "shortName": "Cardiol Therapeutics Inc.", "longName": "Cardiol Therapeutics Inc.", "firstTradeDateEpochUtc": 1547562600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ee9d962b-eed4-3063-8df9-c815990fe5d8", "messageBoardId": "finmb_424954803", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.94, "targetHighPrice": 9.99, "targetLowPrice": 7.99, "targetMeanPrice": 8.99, "targetMedianPrice": 8.99, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 24021236, "totalCashPerShare": 0.344, "ebitda": -31661444, "totalDebt": 164273, "quickRatio": 2.245, "currentRatio": 2.394, "debtToEquity": 1.069, "returnOnAssets": -0.54148996, "returnOnEquity": -1.08435, "freeCashflow": -11630728, "operatingCashflow": -21577782, "financialCurrency": "CAD", "trailingPegRatio": null, "__fetch_time": "2024-09-01"}]